- Home
- ERAS vs CELC Comparison
ERAS vs CELC Comparison
Compare ERAS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- CELC
- Stock Information
- Founded
- ERAS 2018
- CELC 2011
- Country
- ERAS United States
- CELC United States
- Employees
- ERAS N/A
- CELC N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- ERAS Health Care
- CELC Health Care
- Exchange
- ERAS Nasdaq
- CELC Nasdaq
- Market Cap
- ERAS 432.6M
- CELC 391.0M
- IPO Year
- ERAS 2021
- CELC 2017
- Fundamental
- Price
- ERAS $1.37
- CELC $10.11
- Analyst Decision
- ERAS Strong Buy
- CELC Strong Buy
- Analyst Count
- ERAS 6
- CELC 6
- Target Price
- ERAS $4.83
- CELC $30.17
- AVG Volume (30 Days)
- ERAS 1.8M
- CELC 248.4K
- Earning Date
- ERAS 03-20-2025
- CELC 03-31-2025
- Dividend Yield
- ERAS N/A
- CELC N/A
- EPS Growth
- ERAS N/A
- CELC N/A
- EPS
- ERAS N/A
- CELC N/A
- Revenue
- ERAS N/A
- CELC N/A
- Revenue This Year
- ERAS N/A
- CELC $49.98
- Revenue Next Year
- ERAS N/A
- CELC N/A
- P/E Ratio
- ERAS N/A
- CELC N/A
- Revenue Growth
- ERAS N/A
- CELC N/A
- 52 Week Low
- ERAS $1.23
- CELC $8.53
- 52 Week High
- ERAS $3.45
- CELC $22.04
- Technical
- Relative Strength Index (RSI)
- ERAS 39.36
- CELC 43.41
- Support Level
- ERAS $1.40
- CELC $9.98
- Resistance Level
- ERAS $1.61
- CELC $10.70
- Average True Range (ATR)
- ERAS 0.11
- CELC 0.68
- MACD
- ERAS 0.01
- CELC 0.06
- Stochastic Oscillator
- ERAS 4.00
- CELC 28.38
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.